Burkitt Lymphoma

P=N/A, N=1000, Recruiting, French Africa Pediatric Oncology Group | Trial completion date: Dec 2028 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2028

P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027

We also provide a comprehensive overview of the findings convincingly demonstrating that subtyping of BL into EBV-positive and EBV-negative better describes the biological heterogeneity of this lymphoma entity than the historical subtyping into endemic, sporadic, and immunodeficiency-associated. As the distinction of BL from other B-cell lymphomas is important for providing optimal oncological care, we also discuss the differential diagnosis and how this lymphoma can be distinguished from other aggressive B-cell lymphomas.

Results from this study highlight the importance of assessing inter-patient variation in NK cell profiles in conjunction with ADCC sensitivity and EBV type within tumor cells when evaluating clinical outcomes for NK-mediated immunotherapies. EBV type dictates NK cytotoxicity: EBV-T1 BL cells require rituximab for NK killing, while EBV-T2 BL cells are eliminated without antibody assistance, highlighting target-specific immune response to EBV-associated cancers.

P=N/A, N=50, Recruiting, Children's Hospital of Philadelphia | Trial completion date: Jun 2027 --> Feb 2028 | Trial primary completion date: Jun 2026 --> Feb 2027

The combination of KPT-8602 and IFN-γ can activate the pan-apoptotic pathway by upregulating ZBP1, thereby effectively inhibiting the growth of PCNSL. This study presented a promising new combination treatment strategy for PCNSL.

Our study provides a comprehensive assessment of the spectrum of MYC, BCL2, and BCL6 rearrangements based on FISH and IHC analysis results.

P1, N=98, Recruiting, Schrödinger, Inc. | N=52 --> 98 | Trial completion date: Mar 2026 --> Nov 2027 | Trial primary completion date: Mar 2026 --> Nov 2027

P3, N=482, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed

In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.

Primary human VSMCs from subjects with the rs11574 minor allele exhibited reduced mitogen-stimulated proliferation. Taken together, these results provide the first characterization of altered molecular and cellular functions of this disease-associated SNP in ID3 at rs11574.

This case, among the youngest reported uses of commercial Axi-cel for BL, highlights the diagnostic complexity in adolescent lymphoma and demonstrates that CD19 CAR-T therapy can overcome TP53-associated chemoresistance in adolescent BL. It also suggests that integrating molecular profiling and immunotherapy may provide new strategies for managing high-risk, treatment-refractory cases in the adolescent and young adult population.